Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization–verteporfin in photodynamic therapy report 2.
Main finding: Verteporfin therapy significantly reduced the risk of moderate and severe visual acuity loss in subfoveal CNV (occult with no classic) secondary to AMD.
Purpose: To determine if photodynamic therapy with verteporfin can safely reduce the risk of vision loss in subfoveal CNV (occult with no classic) secondary to AMD.
Study type: Randomized clinical trial
Condition: CNV secondary to AMD
Participants: Subfoveal CNV, BCVA 20/100 or better
n=339
Intervention:
Group 1: Verteporfin PDT
Group 2: Placebo
Verteporfin PDT-treated patients received on average five treatments over the 2 years of follow-up.
At 1 year, moderate visual loss for both groups were similar.
At 2 years, there was less moderate visual loss in Verteporfin PDT-treated compared to placebo patients.
Verteporfin
Placebo
Lost at least 15 letters
Total
54%
67%
Occult with no classic
55%
68%
Lost at least 30 letters
Total
30%
47%
Occult with no classic
29%
48%
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive